With recent and impending launches of POC MDx platforms, some industry observers believe the technology could replace some POC immunoassays in a few years.
The Singaporean molecular diagnostics firm, which went into judicial management in March, has new financial backing from a Chinese pharmaceutical firm.
Launched in April, the Japan Agency for Medical Research and Development is charged with streamlining that country's unwieldy funding process.
The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said.
The firm aims to inform consumers about genomics and genetic testing, and open up opportunities for more patients to be included in cancer drug trials.
For every paid myBRCA test performed, the startup said that it will donate a free test.
If CareDx successfully commercializes its cfDNA tests, they would be the firm's first products since AlloMap launched in 2005.
The UK firm is using MALDI-TOF mass spec technology to develop the test as a screening tool for the disorder as early as eight weeks into a pregnancy.
The Houston-based firm said that it would offer the technology as part of its service business first, followed shortly by a kit launch.
The four-year project aims to sequence about 800 kids and their parents to get a clearer idea of the genetic underpinnings of birth defects with unknown causes.
In Nature this week: genetic link between birth weight and adult-onset diseases, and more.
Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.
DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.
Researchers discuss the need for antibody standards at a meeting, NPR reports.